Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vidarabine therapy for severe chronic active Epstein-Barr virus infection
Autore:
Kimura, H; Morita, M; Tsuge, I; Hoshino, Y; Tanaka, N; Ito, Y; Morishima, T;
Indirizzi:
Nagoya Univ, Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 4668550, Japan Nagoya Univ Nagoya Aichi Japan 4668550 a Ku, Nagoya, Aichi 4668550, Japan Nagoya Univ, Sch Med, Dept Hlth Sci, Showa Ku, Nagoya, Aichi 4668550, Japan Nagoya Univ Nagoya Aichi Japan 4668550 a Ku, Nagoya, Aichi 4668550, Japan
Titolo Testata:
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
fascicolo: 5, volume: 23, anno: 2001,
pagine: 294 - 299
SICI:
1077-4114(200106/07)23:5<294:VTFSCA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
EBV INFECTION; CELL-LINE; LYMPHOPROLIFERATIVE DISEASE; VIRAL-DNA; LYMPHOCYTES; PATIENT; ESTABLISHMENT; MONONUCLEOSIS; DISORDER;
Keywords:
Epstein-Barr virus; SCAEBV; vidarabine; quantitative; PCR; in situ hybridization;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Kimura, H Nagoya Univ, Sch Med, Dept Pediat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan Nagoya Univ 65 Tsurumai Cho Nagoya Aichi Japan 4668550 50, Japan
Citazione:
H. Kimura et al., "Vidarabine therapy for severe chronic active Epstein-Barr virus infection", J PED H ONC, 23(5), 2001, pp. 294-299

Abstract

Purpose: Severe chronic active Epstein-Barr virus infection (SCAEBV) is anintractable disease with a poor prognosis, and a definitive treatment has not been established. We administered vidarabine to patients with natural killer (NK) cell-type SCAEBV and evaluated clinical and virologic effects. Patients and Methods: Four patients with SCAEBV were enrolled in this study. These patients had various symptoms, including fever, chronic hepatitis,hepatosplenomegaly. and hypersensitivity to mosquito bites. All patients had increased numbers of NK cells in their peripheral blood, and most of these were infected with EBV. Viral load was measured by in situ hybridizationand quantitative polymerase chain reaction (PCR). Results: The patients all responded to the therapy, and their symptoms improved. After the therapy, the number of NK cells in their peripheral blood decreased. In two patients who were closely monitored, the viral load measured by in situ hybridization and quantitative PCR decreased in parallel with the symptomatic improvement. After discontinuing this drug, the patient'ssymptoms returned and the Epstein-Barr virus load increased again. Conclusion: These results indicate that vidarabine therapy is a therapeutic choice to control SCAEBV, although its effect may be transient.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 14:02:29